Nanorepro AG represents values of innovation, quality, and customer satisfaction in the field of healthcare diagnostics. With a strong focus on research and development, Nanorepro AG aims to provide reliable and user-friendly diagnostic solutions to improve patients' lives. The company's corporate philosophy is centered around delivering accurate and efficient testing products that are accessible to a wide range of users. Nanorepro AG prioritizes continuous improvement and seeks to stay at the forefront of technological advancements in order to address emerging healthcare challenges. By consistently delivering cutting-edge technologies, Nanorepro AG has established itself as a trusted name in the diagnostics industry.

Nanorepro AG, a leading company in the field of medical diagnostics, is primarily present in Germany and other European countries. With its headquarters in Marburg, Germany, Nanorepro AG focuses on developing and distributing innovative rapid testing kits for various health conditions. The company's market penetration extends across Europe, including countries such as Austria, Switzerland, France, Italy, Spain, and the United Kingdom. Nanorepro AG has also expanded its presence in select international markets, aiming to provide its cutting-edge diagnostic solutions globally.

Nanorepro AG, a leading company in the healthcare sector, has achieved several significant milestones. The company successfully developed and launched innovative, easy-to-use medical self-tests, revolutionizing the point-of-care diagnostic market. Nanorepro AG demonstrated impressive revenue growth, expanding its market presence both domestically and internationally. The company's dedication to continuous innovation and research has resulted in the development of cutting-edge technologies, ensuring accuracy and reliability in its products. Nanorepro AG's commitment to customer satisfaction and commitment to quality has garnered recognition and trust from healthcare professionals and end-users alike. Overall, Nanorepro AG's achievements solidify its position as a key player in the healthcare industry.

Nanorepro AG is a German biotechnology company specializing in the development and production of rapid diagnostic tests. Founded in 2006, Nanorepro AG has established itself as a leading player in the field, with a strong focus on innovative healthcare solutions. The company's core areas of expertise include infectious diseases, women's health, and drug testing. Nanorepro AG has a proven track record of delivering reliable and accurate diagnostic tools, empowering healthcare professionals and patients alike. With a commitment to quality and continuous research, Nanorepro AG is dedicated to improving global healthcare outcomes through advanced diagnostic solutions.

The main competitors of Nanorepro AG in the market include companies such as Abbott Laboratories, QIAGEN, Roche Diagnostics, and Thermo Fisher Scientific.

Nanorepro AG is primarily active in the healthcare industry.

The business model of Nanorepro AG, a leading healthcare company, focuses on the development and commercialization of innovative medical diagnostics. Nanorepro specializes in rapid, easy-to-use diagnostics for various medical conditions, including fertility, infectious diseases, allergies, and drug tests. With a strong emphasis on research and development, Nanorepro continuously expands its product portfolio to cater to the evolving healthcare needs of individuals and healthcare professionals worldwide. Through its cutting-edge technologies and strategic partnerships, Nanorepro aims to improve patient outcomes by providing accurate and timely diagnostic solutions.

De K/W-verhouding kan momenteel niet worden berekend voor NanoRepro.

De KUV kan momenteel niet worden berekend voor NanoRepro.

De AlleAktien Kwaliteitsscore voor NanoRepro is 6/10.

De omzet kan momenteel niet worden berekend voor NanoRepro.

De winst kan momenteel niet berekend worden voor NanoRepro.

The Nanorepro AG is an established company in the development and marketing of rapid tests and diagnostics. The business model is based on the production of innovative and reliable medical products that meet the needs in the field of healthcare. The company is divided into three divisions: human medicine, veterinary medicine, and food analysis. In human medicine, Nanorepro AG offers a wide range of rapid tests for self-testing by patients. These rapid tests enable a quick and cost-effective diagnosis of infectious diseases such as HIV, Hepatitis C, and other sexually transmitted diseases. The range also includes fertility tests, self-tests for measuring allergies and cardiovascular diseases, as well as pregnancy tests. The tests are highly popular and sold worldwide under the name "all-in-one." In veterinary medicine, Nanorepro AG offers rapid tests for the diagnosis of animal diseases. The products include a wide range of tests targeting various diseases such as tuberculosis, rabies, brucellosis, and malaria. These tests can be used in animal clinics, animal laboratories, and veterinary practices and contribute to quick diagnosis and treatment. In food analysis, Nanorepro AG develops and distributes specialized test kits for testing food quality and safety. The products include various tests that can detect contamination by bacteria, chemicals, allergens, and genetically modified organisms (GMOs). The tests help ensure the quality and safety of food by detecting potential hazards early. Nanorepro AG is also engaged in research and development of new diagnostics. The company continuously invests in the development of new products to respond to the needs of healthcare and reduce treatment costs. Innovations, such as DNA tests for the identification of tumor mutations, have already been successfully developed and are available on the market. In summary, the business model of Nanorepro AG is focused on a high-quality and wide range of products. The different divisions offer innovative and reliable products for disease diagnosis and food analysis. The company constantly invests in research and development to improve the accuracy and reliability of its products and meet the needs of customers.

NanoRepro keert een dividend van 0,50 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor NanoRepro of het bedrijf keert geen dividend uit.

De ISIN van NanoRepro is DE0006577109.

Het WKN van NanoRepro is 657710.

De ticker van NanoRepro is NN6.DE.

Binnen de laatste 12 maanden betaalde NanoRepro een dividend van 0,50 EUR . Dit komt overeen met een dividendrendement van ongeveer 39,22 %. Voor de komende 12 maanden zal NanoRepro naar verwachting een dividend van 0,50 EUR betalen.

De dividendrendement van NanoRepro is momenteel 39,22 %.

NanoRepro betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

NanoRepro betaalde de afgelopen 1 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0,50 EUR verwacht. Dit komt overeen met een dividendrendement van 36,90 %.

NanoRepro wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van NanoRepro van 20-6-2023 ter hoogte van 0,15 EUR te ontvangen, moest je het aandeel voor de ex-datum op 16-6-2023 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 20-6-2023.

In het jaar 2023 heeft NanoRepro 0 EUR aan dividenden uitgekeerd.

De dividenden van NanoRepro worden in EUR uitgekeerd.